Rapport director granted options on 15,200 shares

Rapport Therapeutics director James Healy received a grant of stock options covering 15,200 shares of common stock.

Rhea-AI Filing Summary

Rapport Therapeutics director James Healy received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.

The 15,200 underlying shares vest on the earlier of June 10, 2027 or the date of Rapport Therapeutics' next Annual Meeting of Stockholders, as long as Healy continues serving the company through that vesting date. After this award, he holds 15,200 derivative securities from this grant.

Insider Trade Summary

Grant/Award: 15,200 shares

Grant/Award 1 txn

Insider HEALY JAMES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,200 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Option grant size: 15,200 shares Exercise price: $35.21 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 15,200 shares Underlying common stock in new option award

Exercise price $35.21 per share Stock option strike price

Expiration date June 10, 2036 Option term end date

Shares after transaction 15,200 derivative securities Total options held from this grant after award

Vesting date trigger June 10, 2027 Latest vesting date, earlier if next annual meeting occurs first

Key Terms

Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vest

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

vest financial

"The shares underlying this option shall vest upon the earlier of"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rapport Therapeutics (RAPP) director James Healy report on this Form 4?

James Healy reported receiving a stock option grant for 15,200 shares of Rapport Therapeutics common stock. The options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price if they vest.

How many Rapport Therapeutics (RAPP) shares are covered by James Healy’s new options?

The new option grant covers 15,200 shares of Rapport Therapeutics common stock. These are potential future shares, only available if the options vest and are exercised, and are separate from any shares currently outstanding in the market.

What is the exercise price and expiry for James Healy’s Rapport Therapeutics options?

The options have an exercise price of $35.21 per share and expire on June 10, 2036. This means Healy can choose to buy shares at $35.21 any time after vesting and before the June 10, 2036 expiration date.

When do James Healy’s Rapport Therapeutics (RAPP) options vest?

The 15,200-share option award vests on the earlier of June 10, 2027 or the date of Rapport Therapeutics’ next Annual Meeting of Stockholders. Vesting requires Healy’s continued service with the company through the applicable vesting date.

Is this Rapport Therapeutics Form 4 a market buy or a compensation grant?

This Form 4 reflects a compensation-related option grant, not a market buy. The transaction code is “A” for grant or award, meaning Healy received options from the company instead of purchasing existing shares on the open market.

How many derivative securities does James Healy hold after this Rapport Therapeutics grant?

Following this transaction, Healy holds 15,200 derivative securities from this option grant. These represent rights to acquire common shares at $35.21 per share if the options vest and he chooses to exercise them before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:26 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEALY JAMES

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.21	06/10/2026		A		15,200		(1)	06/10/2036	Common Stock	15,200	$0	15,200	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)